Ulcerative Colitis (UC) Clinical Trials

49 recruiting

Ulcerative Colitis (UC) Trials at a Glance

51 actively recruiting trials for ulcerative colitis (uc) are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Not Applicable with 13 trials, with the heaviest enrollment activity in Kyiv, Warsaw, and Chisinau. Lead sponsors running ulcerative colitis (uc) studies include Pontificia Universidad Catolica de Chile, Sixth Affiliated Hospital, Sun Yat-sen University, and TIDHI Innovation Inc..

Browse ulcerative colitis (uc) trials by phase

Treatments under study

About Ulcerative Colitis (UC) Clinical Trials

Looking for clinical trials for Ulcerative Colitis (UC)? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ulcerative Colitis (UC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ulcerative Colitis (UC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 51 trials

Recruiting
Not Applicable

Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

Ulcerative Colitis (UC)Mb Crohn
Region Skane160 enrolled1 locationNCT07389161
Recruiting
Not Applicable

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University334 enrolled1 locationNCT06095596
Recruiting
Phase 2

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled251 locationsNCT07415044
Recruiting
Not Applicable

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

Ulcerative Colitis (UC)Rheumatoid Arthritis (RA)Crohn's Disease (CD)
Fuller Research Foundation160 enrolled1 locationNCT07524244
Recruiting

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

Ulcerative Colitis (UC)
Bristol-Myers Squibb150 enrolled17 locationsNCT07271069
Recruiting
Phase 1Phase 2

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)
Mage Biologics100 enrolled1 locationNCT07374471
Recruiting
Phase 1Phase 2

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ulcerative Colitis (UC)
Xencor, Inc.270 enrolled52 locationsNCT06619990
Recruiting
Not Applicable

STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission

Ulcerative Colitis (UC)
University of Chicago200 enrolled1 locationNCT06693310
Recruiting
Phase 2

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

Ulcerative Colitis (UC)
Northwestern University180 enrolled1 locationNCT07427017
Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Indeterminate Colitis+1 more
University of North Carolina, Chapel Hill200 enrolled5 locationsNCT07237516
Recruiting

Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD

Ulcerative Colitis (UC)Crohns Disease
Asian Institute of Gastroenterology, India200 enrolled2 locationsNCT07431983
Recruiting
Phase 2

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Crohn DiseaseUlcerative Colitis (UC)IBD
Assistance Publique - Hôpitaux de Paris45 enrolled1 locationNCT07300553
Recruiting
Phase 2

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Crohn's DiseaseUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
Mirador Therapeutics, Inc.140 enrolled66 locationsNCT07113522
Recruiting
Phase 2

A Study for HSK47388 in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)
Haisco Pharmaceutical Group Co., Ltd.150 enrolled1 locationNCT07335055
Recruiting

Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis

Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University150 enrolled1 locationNCT07442045
Recruiting

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Ulcerative Colitis (UC)Crohn Disease (CD)Inflammatory Bowel Disease (IBD)+1 more
TIDHI Innovation Inc.200 enrolled9 locationsNCT07245394
Recruiting
Phase 2

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)UC - Ulcerative Colitis
Odyssey Therapeutics57 enrolled32 locationsNCT06850727
Recruiting
Phase 2

Desloratadine in Patients With Ulcerative Colitis

Ulcerative ColitisUlcerative Colitis (UC)
Tanta University44 enrolled1 locationNCT07333716
Recruiting
Not Applicable

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Ulcerative Colitis (UC)Crohn Disease (CD)
IRCCS Ospedale San Raffaele80 enrolled1 locationNCT06896305
Recruiting

TRIOCOL - The Study of Continued Advanced Medical Therapy or Colectomy in Patients With Ulcerative Colitis

Ulcerative Colitis (UC)
Region Stockholm500 enrolled1 locationNCT07347834